T cells despite opposing effects on pMHCI tetramer staining. The observed heterogeneity in the ability of anti-CD8 Abs to trigger T cell effector function provides an explanation for the apparent incongruity observed in previous studies and should be taken into consideration when interpreting results generated with these reagents. Furthermore, the ability of Ab-mediated CD8 engagement to deliver an activation signal underscores the importance of CD8 in CD8 + T cell signaling. The Journal of Immunology, 2011, 187: 654-663.
C D8
+ T cells are essential for the control of viral infection and the natural eradication of cancer. CD8 + T cells recognize short peptides, 8-13 aa in length, presented at the target cell surface bound to MHCI molecules. T cell Ag recognition is unique in nature because it involves the binding of a single ligand (peptide-MHC [pMHC]) by two receptors (TCR and coreceptor) (1, 2) . The CD8 glycoprotein, which serves as the coreceptor on MHCI-restricted T cells, acts to enhance the Ag sensitivity of CD8 + T cells by binding to a largely invariant region of MHCI at a site distinct from the TCR docking platform. CD8 has multiple enhancing effects on early T cell activation events, which include the following: 1) promotion and stabilization of TCR/pMHCI binding at the cell surface (3) (4) (5) ; 2) recruitment of essential signaling molecules to the intracellular side of the TCR/ CD3/z complex (6) (7) (8) (9) (10) (11) ; and 3) localization of TCR/pMHCI complexes within specialized membrane microdomains that act as potentially privileged sites for initiation of the TCR-mediated signaling cascade (12, 13) . CD8 binding also controls the level of T cell cross-reactivity (14) and can differentially affect the deployment of CD8 + T cell effector functions (15) . Anti-CD8 Abs have been used widely to investigate the role of CD8 in CD8 + T cell activation. Early studies showed that preincubation with anti-CD8 Abs can block conjugate formation between effector and target cells (16) and inhibit CD8 + T cell activation in response to cognate pMHCI presented on the target cell surface (17) (18) (19) (20) . These findings provided key evidence that CD8 was important in the process of CD8 + T cell activation. However, considerable heterogeneity between different CD8 + T cells was apparent in terms of their ability to activate in the presence of anti-CD8 Abs, and as a result, these reagents were used as tools to classify CD8 + T cells as either CD8 dependent or CD8 independent (21, 22) . Ab-mediated ligation of T cell surface molecules, such as CD2, CD3, and CD28 (23, 24) , can result in effector function. In contrast, studies of Ab-mediated CD8 ligation in the absence of TCR engagement have yielded conflicting results. Early studies demonstrated that induction of CD8 crosslinking at the cell surface can result in p56 lck phosphorylation similar to that seen with anti-CD3 Abs (25) and elicit downstream effector functions, such as chemokine release (26) and potent cytotoxicity (27) . However, in conflict with these data, more re-cent studies suggest that CD8 ligation alone may actually deliver a negative signal (28, 29) .
To date, a cohesive explanation for these widely disparate findings with anti-CD8 Abs has remained elusive. Furthermore, there has been no systematic study of the effects of multiple different anti-human CD8 Abs on CD8 + T cells with different specificities. In this article, we report on the ability of a panel of seven monoclonal anti-human CD8 Abs to induce chemokine/ cytokine release and cytotoxicity by six different human CD8 + T cell clones specific for a total of five different pMHCI Ags. The data, supported by parallel observations in a mouse system, reveal that considerable heterogeneity exists in the ability of anti-CD8 Abs to activate CD8 + T cells. These results elucidate the apparent incongruity that has been observed in previous studies and mandate that the disparate effects of anti-CD8 Abs are considered in the interpretation of results generated with these reagents.
Materials and Methods

Cells
The following HLA A*0201-restricted CD8 + T cell clones were used in this study: 1) ILA1, specific for the human telomerase reverse transcriptase-derived epitope ILAKFLHWL (residues 540-548) (30, 31) ; 2) ALF3, specific for the influenza A matrix protein (M1)-derived epitope GILGFVFTL (residues 58-66); and 3) MEL5 and MEL187.c5, specific for the Melan-A-derived epitope ELAGIGILTV (residues 26-35) (32) . The HLA B*0801-restricted CD8 + T cell clone LC13 is specific for the EBV EBNA3A-derived epitope FLRGRAYGL (residues 339-347) (33) , and the HLA B*3508-restricted CD8 + T cell clone SB10 is specific for the EBV BZLF1-derived epitope LPEPLPQGQLTAY (residues 52-64) (34) . The HLA DR*0101-restricted CD4 + T cell clone C6 recognizes the influenza A hemagglutinin-derived epitope PKYVKQNTLKLAT (residues 307-319). CD8 + T cell lines specific for the EBV BMLF1-derived epitope GLCTLVAML (residues 280-288), restricted by HLA A*0201, were generated as described previously (35) . Naive mouse CD8 + T cells were obtained by harvesting splenocytes from transgenic F5 mice. A significant percentage of CD8 + T cells within the splenic population of these mice express the F5 TCR, which recognizes the H-2D b -restricted influenza H17 nucleoprotein-derived epitope ASNENMDAM (36) . C1R-A*0201 target cells were generated as described previously (37) .
Anti-CD8 Abs
The following anti-human CD8a Ab clones were used in this study: 1) unconjugated or allophycocyanin-conjugated OKT8 (eBioscience, Hatfield, U.K.); 2) unconjugated, FITC-conjugated, or R-PE-conjugated SK1 (BD Biosciences, Oxford, U.K.); 3) unconjugated MCD8 (IqProducts, Groningen, The Netherlands); 4) unconjugated 32/M4 (Santa Cruz Biotechnology, Heidelberg, Germany); 5) unconjugated C8/144B (Santa Cruz Biotechnology); and 6) allophycocyanin-conjugated DK25 (DakoCytomation, Stockport, U.K.). The anti-human CD8b Ab clone 2ST8.5H7 was also used, either in unconjugated or in PE-conjugated form (Abcam, Cambridge, U.K.). In functional assays, the maximum possible Ab concentrations were used, determined by the concentration of the commercially available preparation in each case. For experiments with mouse cells, the following unconjugated anti-mouse CD8 Abs were used: 1) antiCD8a clone CT-CD8a (Caltag-Medsystems, Buckingham, U.K.); 2) antiCD8a clone 53.6.7 (BioLegend, Cambridge, U.K.); 3) anti-CD8b clone KT112 (hybridoma provided by Prof. R. Zamoyska, School of Biological Sciences, University of Edinburgh); and 4) anti-CD8b clone CT-CD8b (Caltag-Medsystems).
Generation of OKT8 Fab, F(ab9) 2 
and Fc9 fragments
A total of 250 mg of the anti-human CD8 Ab OKT8 or the anti-human CD3 Ab OKT3 were digested to yield Fab and Fc9 fragments using a Pierce Fab micropreparation kit (ThermoScientific, Rockford, IL); F(ab9) 2 fragments were produced similarly using a Pierce F(ab9) 2 micropreparation kit (ThermoScientific). IgG fragmentation was performed according to the manufacturer's instructions.
CD8
+ T cell effector function assays
) were mixed with anti-CD8 Abs at the indicated concentrations, either with or without secondary cross-linking by the addition of 5 ml anti-mouse IgG Ab (Beckman Coulter, High Wycombe, U.K.), and incubated overnight at 37˚C in a 5% CO 2 atmosphere. Positive controls included the following: 1) target cells pulsed with 10 27 M cognate peptide; 2) 10 mg/ml anti-human CD3 Ab (UCHT1; BD Biosciences); or 3) 50 ng/ ml PMA and 1 mg/ml ionomycin (Sigma-Aldrich, Dorset, U.K.). Supernatants were harvested and assayed for MIP1a, MIP1b, and RANTES by ELISA (R&D Systems, Abingdon, U.K.) and for IFN-g, TNF-a, and IL-2 by cytometric bead array (Th1/Th2 kit; BD Biosciences), according to the manufacturer's instructions in each case; mouse MIP1b and IL-2 assays were performed by ELISA (R&D Systems). Cytometric bead array (CBA) data were acquired using a FACSCalibur flow cytometer and analyzed with CBA 6 Bead analysis software (BD Biosciences). CD107a mobilization was used to measure T cell degranulation by flow cytometry as described previously (38) . For chromium release assays, 2 3 10 3 T cells were treated with anti-CD8 Abs at the indicated concentrations in 100 ml RPMI 1640 medium (Life Technologies, Paisley, U.K.) supplemented with 100 U/ml penicillin (Life Technologies), 100 mg/ml streptomycin (Life Technologies), 2 mM L-glutamine (Life Technologies), and 2% heat-inactivated FCS (Life Technologies) (R2 medium). C1R-A*0201 target cells ( + T cell lines, 5 3 10 4 cells were preincubated with anti-CD8 Ab as indicated for 25 min on ice and then stained with cognate PE-conjugated HLA A*0201 tetramer (25 mg/ml) at 37˚C for 15 min prior to staining with the amine-reactive fluorescent dye LIVE/DEAD Fixable Aqua (Life Technologies), Pacific Blue-conjugated anti-human CD14 (clone Tuk4; Caltag-Medsystems), Pacific Blue-conjugated anti-human CD19 (clone SJ25-C1; Caltag-Medsystems), PE-Cy5.5-conjugated anti-human CD4 (clone S3.5; Caltag-Medsystems), and FITC-conjugated anti-human CD8 (clone SK1; BD Biosciences) at 4˚C for 20 min. For human PBMCs directly ex vivo, 1 3 10 5 cells were preincubated with anti-CD8 Ab as indicated for 25 min on ice and then stained with allophycocyaninconjugated HLA A*0201 tetramer (25 mg/ml) at 37˚C for 15 min prior to staining with LIVE/DEAD Fixable Aqua (Life Technologies), Pacific Blue-conjugated anti-human CD14 (clone Tuk4; Caltag-Medsystems), Pacific Blue-conjugated anti-human CD19 (clone SJ25-C1; CaltagMedsystems), FITC-conjugated anti-human CD3 (clone HIT3a; BD Biosciences), PE-Cy5.5-conjugated anti-human CD4 (clone S3.5; CaltagMedsystems), and PE-Cy7-conjugated anti-human CD8 (clone RPA-T8; BD Biosciences) at 4˚C for 20 min. For mouse experiments, 5 3 10 4 cells were preincubated with 100 mg/ml CT-CD8a (Caltag-Medsystems), 53.6.7 (BioLegend), KT112 (in-house), or CT-CD8b (Caltag-Medsystems) for 25 min on ice and then stained with cognate PE-conjugated H-2D b tetramer (25 mg/ml) at 37˚C for 15 min prior to staining with LIVE/DEAD Fixable Aqua (Life Technologies), Pacific Blue-conjugated anti-mouse CD4 (clone RM4-5; BD Biosciences), FITC-conjugated anti-mouse CD45R/B220 (clone RA3-6B2; BD Biosciences), and PerCP-Cy5.5-conjugated antimouse CD3 (clone 17A2; BD Biosciences) at 4˚C for 20 min. Data were acquired using either a FACSCantoII or a modified FACSAriaII flow cytometer (both BD Biosciences) and analyzed with FlowJo software (Tree Star, Ashland, OR). medium. A total of 5 3 10 4 PBMCs (unstimulated or stimulated with PHA/IL-15) were resuspended in the presence of 1 ml/ml brefeldin A (GolgiPlug; Sigma-Aldrich), 0.7 ml/ml monensin (GolgiStop; BD Biosciences), and 5 ml/ml anti-CD107a-FITC (clone H4A3; BD Biosciences) and then incubated with anti-human CD8 Abs at the indicated concentrations for 18 h at 37˚C in a 5% CO 2 atmosphere. After washing with PBS, cells were stained with LIVE/DEAD Fixable Violet (ViViD; Life Technologies), Pacific Blue-conjugated anti-human CD14 (clone Tuk4; Caltag-Medsystems), and Pacific Blue-conjugated anti-human CD19 (clone SJ25-C1; Caltag-Medsystems) at room temperature for 15 min. Subsequently, cells were washed and stained with H7-allophycocyaninconjugated anti-human CD3 (clone SK7; BD Biosciences) and PE-Cy5.5-conjugated anti-human CD4 (clone S3.5; Caltag-Medsystems) at 4˚C for 20 min, then washed an additional three times, resuspended in 200 ml BD Cytofix/Cytoperm, and incubated at 4˚C for 20 min. After three additional washes in Perm/Wash (BD Biosciences), cells were stained with PE-Cy7-conjugated anti-human IFN-g (clone B27; BD Biosciences), allophycocyanin-conjugated anti-human TNF-a (clone MAb11; BD Biosciences), and PE-conjugated anti-human MIP1b (clone D21-1351; BD Biosciences) at 4˚C for 20 min, washed again three more times, and resuspended in 200 ml Perm/Wash. Data were acquired using a modified FACSAriaII flow cytometer (BD Biosciences) and analyzed with FlowJo software (Tree Star).
Tetramer kinetics experiments
For tetramer association assays, 5 3 10 5 CD8 + T cells were washed twice and resuspended in 200 ml PBS with or without anti-human CD8 Ab and then incubated with cognate tetramer (5 mg/ml). At indicated time points, 12 ml of the cell suspension was removed and acquired using a FACSCalibur flow cytometer (BD Biosciences). Data were analyzed using FlowJo software (Tree Star). Tetramer decay analysis was performed as described previously (3).
Surface plasmon resonance analysis
Soluble TCRs derived from the MEL5 and MEL187.c5 CD8 + T cell clones were manufactured as described previously (40) (41) (42) . Binding analysis was performed using a BIAcore 3000 equipped with a CM5 sensor chip (43) . Between 200 and 400 response units of biotinylated pMHCI was immobilized to streptavidin, which was chemically linked to the chip surface. The pMHCI was injected at a slow flow rate (10 ml/min) to ensure uniform distribution on the chip surface. Combined with the small amount of pMHCI bound to the chip surface, this reduced the likelihood of off-rate limiting mass transfer effects. The MEL5 TCR and MEL187.c5 TCRs were purified and concentrated to ∼100 mM on the day of surface plasmon resonance analysis to reduce the likelihood of TCR aggregation affecting the results. For equilibrium analysis, eight serial dilutions were carefully prepared in triplicate for each sample and injected over the relevant sensor chips at 25˚C. The TCRs were injected over the chip surface at a flow rate of 45 ml/min. Results were analyzed using BIAevaluation 3.1, Microsoft Excel, and Origin 6.1. The equilibrium binding constant (K D ) values were calculated using a nonlinear curve fit (y = [
Results
Anti-CD8 Abs can trigger T cell effector function in the absence of TCR engagement
Several studies suggest that Ab-mediated ligation of CD8 in the absence of TCR engagement can elicit downstream effector function (25) (26) (27) ; however, others have reported the delivery of negative signals with this manipulation (28, 29) . To reconcile these apparently disparate findings, we conducted a systematic study of the effects of multiple different anti-human CD8 Abs on CD8 + T cells with several different specificities. For this purpose, we used a panel of anti-human CD8 Abs that comprised six antiCD8a Abs (OKT8, SK1, MCD8, 32/M4, C8/144B, and DK25) and one anti-CD8b Ab (2ST8.5H7). Six of seven anti-human CD8 Abs from the panel (SK1, MCD8, 32/M4, C8/144B, DK25, and 2ST8.5H7) did not elicit any chemokine production when incubated with four different HLA A*0201-restricted CD8 + T cell clones (ILA1, ALF3, MEL5, and MEL187.c5) with a total of three different specificities in the absence of specific pMHCI Ag (Fig.  1) . However, the anti-CD8a Ab OKT8 induced MIP1a, MIP1b, and RANTES release from all four HLA A*0201-restricted CD8 + T cell clones (Fig. 1) . Chemokine secretion was apparent over a range of OKT8 concentrations (Supplemental Fig. 1 ).
In addition, we measured chemokine release by two non-HLA A*0201-restricted CD8 + T cell clones following incubation with each anti-human CD8 Ab from the panel. Both of these non-HLA A*0201-restricted CD8 + T cell clones produced MIP1a, MIP1b, and RANTES in response to OKT8 but did not activate in the presence of the other Abs tested (Fig. 2) . Remarkably, the highly Ag-sensitive HLA B*3508-restricted EBV BZLF1-specific CD8 + T cell clone SB10 released .2000 pg/ml of each chemokine in response to OKT8 (Fig. 2B) . OKT8 was incapable of staining the HLA DR*0101-restricted CD4 + T cell clone C6 (Supplemental Fig. 2A ) and failed to induce chemokine release from this clone (Supplemental Fig. 2B-D) . Thus, the stimulatory effects of OKT8 appear to be CD8 + T cell specific. The panel of seven anti-human CD8 Abs was further tested in cytotoxicity assays with four different CD8 + T cell clones (MEL187.c5, ALF3, LC13, and SB10). Anti-human CD8 Abs that were incapable of inducing chemokine release failed to elicit cytotoxic activity in any of these four CD8 + T cell clones (Fig. 3) . In contrast, SB10 CD8 + T cells exhibited substantial cytotoxicity in response to stimulation with OKT8; lower levels of specific lysis + T cells (D) were incubated for 18 h with each of the following individual anti-human CD8 Abs in parallel: 100 mg/ml OKT8, 6.25 mg/ml SK1, 50 mg/ml MCD8, 100 mg/ml 32/M4, 100 mg/ml C8/144B, 25 mg/ml DK25, and 100 mg/ml 2ST8.5H7 (CD8b). The maximum possible Ab concentrations were used, determined by the concentration of the commercially available preparation in each case. were also induced in the CD8 + T cell clones LC13 (3.18%), ALF3 (5.1%), and MEL187.c5 (3.8%) ( Fig. 3 ; data not shown). These results are consistent with a previous study that described a mouse anti-CD8 Ab, KT112, capable of inducing cytotoxicity (27) . Collectively, these data indicate that considerable heterogeneity exists in the ability of anti-CD8 Abs to activate CD8 + T cells.
OKT8 induces chemokine secretion in the absence of cytokine secretion
Next, we examined the ability of Ab-mediated CD8 ligation to elicit cytokine release by CD8 + T cells in the absence of TCR engagement. As expected, the anti-human CD8 Abs that did not elicit chemokine release or cytotoxic activity (SK1, MCD8, 32/M4, C8/ 144B, DK25, and 2ST8.5H7) also failed to induce IFN-g, TNF-a, or IL-2 release (Fig. 4) . Interestingly, OKT8 similarly failed to elicit cytokine production from the majority of CD8 + T cell clones tested (Fig. 4) . Importantly, chemokine and cytokine assays were performed using the same supernatant, thereby confirming that OKT8 stimulated CD8 + T cells to secrete chemokines in the absence of cytokine production; one exception to this dichotomy occurred with the CD8 + T cell clone SB10, which released IFN-g in response to treatment with OKT8. These data suggest that OKT8-mediated CD8 ligation delivers a signal that falls below the threshold required for cytokine production in most CD8 + T cells.
Neither secondary Ab cross-linking nor PHA/IL-15 treatment alter the functional phenotype of anti-human CD8 Abs
To probe the possibility that the degree of cross-linking mediated by each of the anti-human CD8 Abs tested could explain the functional heterogeneity observed between these reagents, we performed activation experiments with the addition of secondary Abs. Secondary cross-linking of OKT8 increased the level of MIP1a, MIP1b, and RANTES release by ILA1, ALF3, MEL5, MEL187.c5, LC13, and SB10 CD8 + T cells above that observed with OKT8 alone (Fig. 5; data not shown) . However, secondary Ab-mediated cross-linking did not reverse the phenotype of the nonactivating anti-human CD8 Abs (Fig. 5) .
We also examined the effect of PHA/IL-15 treatment on the ability of anti-human CD8 Abs to elicit effector function from CD8 + T cells in healthy donor PBMCs. PHA is capable of crosslinking glycosylated proteins at the T cell surface. The seven antihuman CD8 Abs tested did not substantially activate CD8 + T cells in untreated PBMCs (Fig. 6A) . The six nonactivating anti-human CD8 Abs also failed to induce substantial levels of CD8 + T cell activation in PBMCs cultured for 7 d in PHA/IL-15 (Fig. 6B) . In contrast, OKT8 activated CD8 + T cells in PHA/IL-15-stimulated PBMCs to release MIP1b and degranulate as measured by surface mobilization of CD107a. Interestingly, OKT8 also induced IFN-g The anti-human CD8 Ab OKT8 can trigger cytotoxic activity. A total of 2 3 10 3 LC13 CD8 + T cells (A) or SB10 CD8 + T cells (B) were incubated with each of the following individual anti-human CD8 Abs in parallel: 100 mg/ml OKT8, 6.25 mg/ml SK1, 50 mg/ml MCD8, 100 mg/ ml 32/M4, 100 mg/ml C8/144B, 25 mg/ml DK25, and 100 mg/ml 2ST8.5H7 (CD8b). The anti-human CD3 Ab UCHT1 (10 mg/ml) served as a positive control. Cytotoxicity assays were then performed over a period of 18 h as described in Materials and Methods using 51 Cr-labeled C1R-A*0201 B cells as targets. Error bars represent SDs. + T cells were incubated for 18 h with each of the following individual anti-human CD8 Abs in parallel: 100 mg/ ml OKT8, 6.25 mg/ml SK1, 50 mg/ml MCD8, 100 mg/ml 32/M4, 100 mg/ ml C8/144B, 25 mg/ml DK25, and 100 mg/ml 2ST8.5H7 (CD8b). The anti-human CD3 Ab UCHT1 (10 mg/ml) served as a positive control. Supernatant was harvested and assayed for IFN-g (A), TNF-a (B), and IL-2 (C) by CBA. were incubated for 18 h with each of the following individual anti-human CD8 Abs in parallel: 100 mg/ ml OKT8, 6.25 mg/ml SK1, 50 mg/ml MCD8, 100 mg/ml 32/M4, 100 mg/ ml C8/144B, 25 mg/ml DK25, and 100 mg/ml 2ST8.5H7 (CD8b + T cells were preincubated at 4˚C for 25 min with each of the following individual anti-human CD8 Abs in parallel: 100 mg/ml OKT8, 6.25 mg/ml SK1, 50 mg/ml MCD8, 100 mg/ml 32/M4, 100 mg/ ml C8/144B (144B), 25 mg/ml DK25, and 100 mg/ml 2ST8.5H7 (CD8b). CD8 + T cells were subsequently stained with cognate PE-conjugated HLA A*0201 tetramers (25 mg/ ml) and 7-aminoactinomycin D as described in Materials and Methods. Data were acquired using a FACSCalibur flow cytometer and analyzed with FlowJo software. Relative median fluorescence intensity (MFI) values with respect to pMHCI tetramer staining in the absence of preincubation with anti-CD8 Ab are shown. Fluorescence in the absence of added cognate tetramer (con) is shown in each case. Data are representative of four separate experiments using ILA1 and ALF3 CD8 + T cells, and six separate experiments using MEL5 and MEL187.c5 CD8 + T cells. PBMCs were then incubated for 18 h with each of the following individual anti-human CD8 Abs in parallel: 100 mg/ml OKT8, 6.25 mg/ml SK1, 50 mg/ml MCD8, 100 mg/ml 32/M4, 100 mg/ml C8/ 144B, 25 mg/ml DK25, and 100 mg/ml 2ST8.5H7 (CD8b). The anti-human CD3 Ab UCHT1 (10 mg/ml) served as a positive control. CD8 + T cell effector functions were measured by intracellular cytokine staining and surface CD107a mobilization as described in Materials and Methods. Data were acquired using a modified FACSAriaII flow cytometer and analyzed with FlowJo software. Results obtained by gating on either the CD3 + CD4 2 (A, B) or CD4 + (C) population are shown for a representative experiment (n = 2). Minor differences in background levels of CD8 + T cell activation were observed with the non-OKT8 anti-human CD8 Abs (A, B); this may reflect heterogeneity within the CD8 + PBMC population.
FIGURE 5. Secondary crosslinking does not alter the functional phenotype of anti-human CD8 Abs. A total of 3 3 10 4 ILA1 CD8 + T cells were incubated with each of the following individual anti-human CD8 Abs in parallel: 100 mg/ml OKT8, 6.25 mg/ml SK1, 50 mg/ml MCD8, 100 mg/ ml 32/M4, 100 mg/ml C8/144B, 25 mg/ml DK25, and 100 mg/ml 2ST8.5H7 (CD8b). The positive control comprised 3 3 10 4 C1R-A*0201 B cells pulsed with cognate peptide at 10 27 M. Abs were then cross-linked with the addition of 5 ml anti-mouse IgG Ab (serum IgG) and incubated for 18 h at 37˚C in a 5% CO 2 atmosphere. Supernatant was harvested and assayed for MIP1a (A), MIP1b (B), and RANTES (C) by ELISA. Secondary cross-linking of OKT8 increased the levels of all analytes measured; this also applied to anti-CD3 Ab-induced chemokine release (data not shown). Similar results were obtained with all other CD8 + T cell clones tested: ALF3, MEL5, MEL187.c5, LC13, and SB10 (data not shown). Error bars represent SDs.
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PBMCs (Fig. 6C) , consistent with previously discussed data (Supplemental Fig. 2 ).
OKT8 enhances pMHCI tetramer staining
Next, we tested the effects of anti-human CD8 Abs on the staining of ILA1, ALF3, MEL5, and MEL187.c5 CD8 + T cells with cognate pMHCI tetramers. Three anti-human CD8 Ab clones (SK1, DK25, and 2ST8.5H7) inhibited tetramer staining; clones MCD8, 32/M4, and C8/144B had little or no effect on staining. However, preincubation with OKT8 enhanced cognate pMHCI tetramer staining of all four CD8 + T cell clones (Fig. 7) . Thus, OKT8 can enhance the binding of pMHCI tetramers in a range of systems. These findings suggested that OKT8 might facilitate the identification of Ag-specific CD8 + T cells within mixed cell populations. To test this idea, we examined pMHCI tetramer staining of CD8 + T cell lines raised against the HLA A*0201-restricted EBV BMLF1-derived epitope GLCTLVAML (residues 280-288). OKT8 enhanced the staining intensity of cognate CD8 + T cells with the relevant pMHCI tetramer without concomitant increases in noncognate HLA A*0201 tetramer binding (Fig. 8A,  8B) . No increase in the percentage of tetramer + CD8 + cells was observed in the presence of OKT8 (Fig. 8A, 8B) , which likely reflects the high-affinity TCR/pMHCI interactions that characterize antiviral CD8 + T cell populations (41) . We hypothesized that OKT8-mediated enhancement of TCR/ pMHCI binding at the cell surface might have beneficial effects on pMHCI tetramer staining with low-affinity ligands, an effect that could prove very useful for the detection of CD8 + T cells with TCRs that bind weakly to cognate Ag, such as those that appear to predominate in anticancer and autoimmune responses (32, 41) . To test this hypothesis, we used two monoclonal CD8 + T cell systems and a series of altered peptide ligands that vary in their affinity for cognate TCR by .5-fold (Table I, Supplemental Fig. 3 ). Preincubation with OKT8 enhanced staining efficiency with all variant pMHCI tetramers, including low-affinity variants (Table I , Supplemental Fig. 4) . Consistent with this finding, OKT8 increased both the staining intensity and the percentage of Agspecific events detected when CD8 + T cell lines raised against the HLA A*0201-restricted Melan-A-derived epitope ELAGI-GILTV (residues 26-35) were stained with HLA A*0201 tetramers folded around the low-affinity peptide variants FLAGIGILTV or ELTGIGILTV (Fig. 8C, 8D ).
OKT8 enhances TCR/pMHCI on-rates at the cell surface
To examine how OKT8 enhances Ag binding at the CD8 + T cell surface in more detail, we examined the effects of this Ab on TCR/pMHCI kinetics using pMHCI tetramers. Differences in tetramer off-rates were minimal (data not shown). However, pretreatment of CD8 + T cells with OKT8 resulted in a significant increase in the TCR/pMHCI on-rate at the cell surface in each CD8 + T cell clone tested (Fig. 9) . In contrast, DK25 inhibited pMHCI tetramer binding at the cell surface (Fig. 9B) . OKT8 Ab-FIGURE 8. OKT8 enhances pMHCI tetramer staining in mixed cell populations. A and B, A total of 5 3 10 4 cells from a CD8 + T cell line primed with the EBV BMLF1-derived epitope GLCTLVAML (residues 280-288) were either mock treated or incubated with 100 mg/ml OKT8 at 4˚C for 25 min and then stained with either noncognate HLA A*0201-ELAGIGILTV (A) or cognate HLA A*0201-GLCTLVAML (B) APC-conjugated tetramer (25 mg/ml each) at 37˚C for 15 min. C and D, A total of 5 3 10 4 cells from a CD8 + T cell line primed with the Melan-A-derived epitope ELAGIGILTV (residues 26-35) were either mock treated or incubated with 100 mg/ml OKT8 at 4˚C for 25 min and then stained with either HLA A*0201-FLA-GIGILTV (C) or HLA A*0201-ELTGIGILTV (D) PE-conjugated tetramer (25mg/ml each) at 37˚C for 15 min. Additional stains were performed as detailed in Materials and Methods. Data were acquired using a FACSCantoII flow cytometer and analyzed with FlowJo software. Summary of equilibrium binding analysis of MEL5 and MEL187.c5 TCRs with pMHCI variants and the effect of OKT8 on HLA A*0201 tetramer staining. Raw surface plasmon resonance data are shown in Supplemental Fig. 3 ; flow cytometry data are shown in Supplemental Fig. 4 . www.jimmunol.org induced enhancement of pMHCI tetramer on-rates was also apparent with CD8-null tetramers (Fig. 9C) . Collectively, these data indicate that OKT8 enhances pMHCI tetramer staining by increasing the on-rate. Furthermore, OKT8 Ab-mediated augmentation of Ag binding at the cell surface occurs independently of the pMHCI/CD8 interaction.
OKT8 F(ab9) 2 fragments can enhance tetramer staining and elicit CD8 + T cell effector function
Abs can be digested by papain or pepsin to produce Fab or F(ab9) 2 fragments, respectively. These enzymatically generated fragments have been used extensively in the past to study the structure and function of Abs. We examined the ability of OKT8 Fab and F(ab9) 2 fragments to enhance pMHCI tetramer staining and to induce chemokine release in the absence of TCR engagement. Not surprisingly, Fab fragments of OKT8 failed to activate CD8 + T cells or enhance pMHCI tetramer staining (Fig. 10A, 10B) . Interestingly, however, OKT8 F(ab9) 2 fragments retained some ability to enhance pMHCI tetramer staining and elicit chemokine release (Fig. 10A, 10B ). OKT8-mediated effects were diminished by pepsin digestion, but anti-human CD3 Abs were similarly impaired functionally after digestion with this enzyme (Fig. 10C) ; this latter effect has been described previously (44) (45) (46) . Thus, it appears that intact OKT8 exerts effects on pMHCI tetramer binding and CD8 + T cell activation more efficiently than derived F(ab9) 2 fragments. However, cellular activation by OKT8 F(ab9) 2 fragments confirms that this effect is not entirely Fc9 dependent.
Anti-mouse CD8 Abs can trigger CD8
+ T cell effector function in the absence of TCR engagement
To extend these findings beyond human systems (summarized in Table II) , we examined the effects of the anti-mouse CD8a Ab CT-CD8a and the anti-mouse CD8b Ab CT-CD8b on pMHCI tetramer staining and CD8 + T cell activation in the absence of TCR engagement. We observed that CT-CD8a inhibited tetramer staining of mouse transgenic F5 CD8 + T cells, whereas CT-CD8b enhanced tetramer staining of the same Ag-specific population (Fig. 11A) . These results are consistent with our previous findings (26) . Interestingly, despite opposing effects on pMHCI tetramer staining, both of these anti-mouse CD8 Abs induced MIP1b production in the absence of TCR engagement from both naive and Ag-exposed F5 CD8 + T cells ( Fig. 11B ; data not shown). These effects were shown to be CD8-specific and occurred in the absence of any concomitant IL-2 release (data not shown). The anti-mouse CD8 Abs 53.6.7 and KT112 both enhanced pMHCI tetramer staining and induced small amounts of MIP1b production T cells were either mock treated or incubated with 100 mg/ml OKT8, 100 mg/ml OKT8 Fab, or 100 mg/ml OKT8 F(ab9) 2 and then stained with PEconjugated HLA A*0201-ELAGIGILTV tetramer (25 mg/ml) as described in Materials and Methods. Data were acquired using a FACSCantoII flow cytometer and analyzed with FlowJo software. B, A total of 3 3 10 4 MEL5 or ALF3 CD8 + T cells were incubated with 100 mg/ml OKT8, 100 mg/ml OKT8 Fab, 100 mg/ml OKT8 F(ab9) 2 , or 100 mg/ml OKT8 Fc9 for 18 h. Supernatant was harvested and assayed for MIP1a, MIP1b, and RANTES by ELISA. C, A total of 3 3 10 4 MEL5 or ALF3 CD8 + T cells were incubated with either 10 mg/ml OKT3 or 10 mg/ml OKT3 F(ab9) 2 for 18 h. Supernatant was harvested and assayed for MIP1a, MIP1b, and RANTES by ELISA (only MIP1b is shown). Data in A-C are representative of three separate experiments. Error bars represent SDs. FIGURE 9. OKT8 increases TCR/pMHCI on-rates at the cell surface. A total of 5 3 10 5 ILA1 (A) or ALF3 (B, C) CD8 + T cells were removed from culture, washed twice, and resuspended in 100 ml PBS with or without 100 mg/ml OKT8 or 25 mg/ml DK25 and then incubated at 4˚C for 25 min. Cognate PE-conjugated HLA A*0201 tetramer was added in each case at 5 mg/ml. At various time points as indicated, 12 ml cell suspension was removed and acquired using a FACSCalibur flow cytometer and analyzed with FlowJo software. In C, the CD8-null (D227K/T228A) cognate HLA A*0201 tetramer was used (10).
( Fig. 11A, 11B) . Thus, three different phenotypes were identified within a panel of four different anti-mouse CD8 Abs (Table III) , which further underscores the considerable heterogeneity that exists within this group of reagents.
Discussion
Anti-CD8 Abs are integral to the flow cytometric detection of pMHCI-restricted T cells and have been used extensively in the past to identify an important role for CD8 in CD8 + T cell activation (16) (17) (18) 20) . Most studies have concluded that anti-CD8 Abs inhibit the recognition of cognate Ag (19, 21, 22) . Furthermore, a recent study provided evidence that a single anti-CD8 Ab could deliver a negative signal to a CD8 + T cell clone in the absence of cognate Ag (29) . In contrast, however, earlier studies concluded that anti-CD8 Abs could activate CD8 + T cells (25, 27) . Thus, contradictory effects of Ab-mediated CD8 ligation have been reported and the overall picture remains unclear. To clarify this issue, we examined the ability of seven different monoclonal antihuman CD8 Abs to activate six different human CD8 + T cell clones specific for a total of five different pMHCI Ags.
In the absence of cognate Ag, the anti-human CD8 Ab OKT8 induced chemokine release from all six human CD8 + T cell clones tested and cytotoxic activity in all four human CD8 + T cell clones tested (Figs. 1-3) . Interestingly, this activation appeared to occur in the absence of any detectable cytokine release, with the exception of CD8 + T cell clone SB10, which released IFN-g (Fig. 4) . It is well established that a hierarchy of CD8 + T cell effector functions exists with respect to Ag sensitivity (47, 48) ; thus, each function exhibits a distinct activation threshold that must be exceeded for triggering to occur. Our findings suggest that OKT8 delivers a positive signal to CD8 + T cells that is generally sufficient to exceed the activation threshold required for chemokine release and cytotoxic activity but is not sufficient to trigger cytokine release in the majority of CD8 + T cells. In contrast to OKT8, the anti-human CD8a Ab clones SK1, MCD8, C8/144B, 32/M4, and DK25 as well as the anti-human CD8b Ab clone 2ST8.5H7 did not induce any measurable T cell effector functions in the absence of cognate Ag. It was not possible to reverse the phenotype of the nonactivating anti-human CD8 Abs by secondary Ab-mediated cross-linking or PHA/IL-15 treatment (Figs. 5, 6 ). Thus, we conclude that anti-CD8 Abs can exert differential effects on CD8 + T cells. These findings help to reconcile disparate observations and suggest that previous reports in the literature may not be intrinsically contradictory but rather reflective of the considerable heterogeneity that characterizes the ability of anti-CD8 Abs to induce CD8 + T cell effector function. Anti-CD8 Ab-mediated activation of CD8 + T cells is consistent with a recent report, in which we demonstrated that MHCI molecules with superenhanced CD8 binding properties can also activate CD8 + T cells in the absence of a specific TCR/pMHCI interaction (49) . Furthermore, thymus leukemia Ag interacts strongly (K D = 12 mM) with cell surface CD8aa expressed by intraepithelial lymphocytes and can modulate T cell responses independently of the TCR (50) (51) (52) . These studies all demonstrate that the engagement of CD8 in the absence of cognate Ag binding to the TCR can activate CD8 + T cells and, collectively, underscore the importance of CD8 in T cell signaling.
To examine the effects of OKT8 on Ag binding at the CD8 + T cell surface, we used soluble pMHCI tetramer technology, which has transformed the study of Ag-specific CD8 + T cells by FIGURE 11 . Anti-mouse CD8 Abs can exhibit the same phenotype as OKT8. A, A total of 5 3 10 4 naive mouse transgenic F5 T cells were either mock treated or incubated with 100 mg/ml CT-CD8a, 100 mg/ml 53.6.7, 100 mg/ml CT-CD8b, or 100 mg/ml KT112 at 4˚C for 25 min and then stained with cognate PE-conjugated H-2D b tetramer (25mg/ml) as described in Materials and Methods. No staining was observed under any of the conditions shown with a control H-2D b tetramer folded around the lymphocytic choriomeningitis virus GP1-derived epitope KAVYNFATC (residues 33-41). Data were acquired using a modified FACSAriaII flow cytometer and analyzed with FlowJo software. Results were obtained by gating on the CD3 + CD4 2 population. B, A total of 3 3 10 4 naive mouse transgenic F5 T cells were incubated at 37˚C for 18 h with 100 mg/ml CTCD8a, 100 mg/ml 53.6.7, 100 mg/ml CT-CD8b, 100 mg/ml KT112, or 50 ng/ml PMA and 1 mg/ml ionomycin. Supernatants were harvested and assayed for MIP1b by ELISA. Error bars represent SDs. (Figs. 7-9 ). Accordingly, OKT8 enhanced the identification of CD8 + T cells with low-affinity TCR/pMHCI interactions (Fig. 8, Table I ), such as those that typically predominate in tumor-specific and autoimmune responses (41) . The other anti-CD8 Abs examined in this study either exerted inhibitory effects on pMHCI tetramer binding (SK1, DK25, and 2ST8.5H7) or displayed no biologically significant activity in this regard (MCD8, 32/M4, and C8/144B). Thus, OKT8 can be used as a tool to improve pMHCI tetramer staining; this property may be especially useful in the context of low-avidity Ag-specific CD8 + T cell populations. The findings described above suggest that OKT8 has properties that are distinct from other anti-human CD8 Abs. Furthermore, these properties are not entirely Fc9 dependent (Fig. 10) . To extend these results, we conducted additional experiments with the antimouse CD8a Ab CT-CD8a and the anti-mouse CD8b Ab CTCD8b. CT-CD8a was shown to inhibit pMHCI tetramer staining, whereas CT-CD8b enhanced pMHCI tetramer binding, consistent with a previous report (26) . Despite their differential effects on pMHCI tetramer binding, both of these anti-mouse CD8 Abs activated CD8 + T cells efficiently (Fig. 11) . These results demonstrate that the ability of anti-CD8 Abs to elicit CD8 + T cell effector function does not always correlate with their effect on pMHCI tetramer staining. This lack of correspondence was further supported by the identification of a third phenotype in the mouse system. The anti-mouse CD8a Ab 53.6.7 and the antimouse CD8b Ab KT112 both enhanced pMHCI tetramer staining but only activated CD8 + T cells weakly (Table III) . Taken together, these data further underline the heterogeneity that exists within this group of reagents.
The mechanism by which anti-CD8 Abs exert either inhibitory or stimulatory effects on pMHCI recognition remains elusive. Previous studies have shown that anti-CD8 Abs retain their effects in the absence of a pMHCI/CD8 interaction (26, (53) (54) (55) . In this study, we confirm that the enhancing effects of OKT8 on HLA A*0201 tetramer on-rate at the cell surface are still apparent in the context of CD8-null MHCI molecules (Fig. 9) ; thus, these effects are independent of any interaction between pMHCI and CD8. Subtle local rearrangements of the TCR relative to CD8 on pMHCI engagement are required for optimal CD8 + T cell activation (56, 57) . By extension, it seems likely that anti-CD8 Abs exert their effects by interfering with, or enhancing, this surface receptor topology. The observation that anti-CD4 Abs can block cell surface intermolecular interactions essential for calcium flux and inhibit subsequent synapse formation is consistent with this hypothesis (58) . Furthermore, we have previously demonstrated that anti-CD4 Abs can interfere with pMHCII tetramer binding even though the pMHCII/CD4 interaction does not stabilize TCR/ pMHCII interactions (59) .
In summary, we have shown the following: 1) heterogeneity exists in the ability of anti-CD8 Abs to activate CD8 + T cells; 2) Ab-mediated ligation of CD8 in the absence of TCR engagement can induce chemokine release and cytotoxic activity, largely in the absence of cytokine release; 3) the anti-human CD8 Ab OKT8 can enhance pMHCI tetramer staining; and 4) anti-mouse CD8 Abs (CT-CD8a and CT-CD8b) can activate CD8 + T cells in the absence of TCR engagement despite differential effects on pMHCI tetramer staining. Thus, anti-CD8 Abs can have potent effects on TCR/pMHCI binding kinetics and activation. These effects vary according to the Ab clone under investigation and should be taken into account when interpreting studies using these reagents. Furthermore, the ability of Ab-mediated CD8 engagement to activate CD8 + T cells underscores the importance of coreceptor function in CD8 + T cell signaling.
